Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. Graduate Institute of Clinical Medicine / 臨床醫學研究所
  4. Cytoskeleton reorganization by thymosin beta-4 alters fate determination of human mesenchymal stem cells
 
  • Details
Options

Cytoskeleton reorganization by thymosin beta-4 alters fate determination of human mesenchymal stem cells

Type
conference
Resource
Sep 2008 Taiwan Society for Stem Cell Research Annual Meeting (Taipei; Taiwan)
Date Issued
2008
Author(s)
何慧君
Ho JH; Ma WH; Tseng KC; Makino H; Kuo TK; Su Y; Oscar Lee
Subjects
臨床醫學研究所
會議論文
URI
https://203.71.86.71/handle/123456789/31482

Copyright Notice

● The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use.

● Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner. Users must not use TMUIR for any illegal purposes.

● By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in this statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions.

● TMUIR is committed to protecting the interests of copyright owners. If you believe that any material on this website infringes copyright, please contact our staff at libirtmu@gmail.com, and we will remove the work from the repository.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback